 AIM ImmunoTech Inc NYSE: AIM has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive Dysfunction PCCD. The meeting request has been deemed sufficient for transfer to the FDAs Division of Neurology by the FDAs COVID Scientific Technical Triage Team. 